| Similar Articles |
|---|
 |
The Motley Fool
April 24, 2009
Brian Orelli |
The Economy Strikes Again Amgen isn't recession-proof either.   |
The Motley Fool
July 12, 2004
Ben McClure |
Falling for Amgen Ahead of its second-quarter earnings release, the biotech giant looks good. |
The Motley Fool
September 6, 2007
Brian Lawler |
Amgen's Congressional Helpers Lawmakers push to ease restrictions on anemia compounds from Amgen and Johnson & Johnson. Investors, take note. |
The Motley Fool
October 25, 2011
Brian Orelli |
Anemic Growth in All the Right Places Amgen's anemia drugs decline, but that's not its future anyway. |
BusinessWeek
June 4, 2007
Gene G. Marcial |
Amgen Believers There has been a deluge of bad news at biotech Amgen, whose stock has tumbled. |
The Motley Fool
October 22, 2009
Brian Orelli |
Good Luck in 2010, Amgen Just when it looked like Amgen was turning things around the Food and Drug Administration threw a wrench in the biotech's plans for its osteoporosis drug Prolia. |
The Motley Fool
April 28, 2008
Brian Lawler |
Amgen's Anemic Earnings Drug troubles and potential label changes continue to hurt Amgen's earnings. |
The Motley Fool
March 29, 2004
Jeff Hwang |
Amgen Deals Again Two years after acquiring Immunex, Amgen takes Tularik. |
The Motley Fool
March 25, 2010
Brian Orelli |
More Than $5.3 Billion in Revenue Under Attack After dealing with the FDA, Amgen and J&J now have to deal with the Centers for Medicare & Medicaid Services. |
The Motley Fool
May 14, 2007
Mike Havrilla |
A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs. |
The Motley Fool
April 24, 2007
Ryan Fuhrmann |
Red and White Results at Amgen At current levels, this biotech titan could be worth a further look from investors. |
The Motley Fool
April 24, 2007
Brian Lawler |
Amgen On Sale? Biotech giant Amgen announces first-quarter financial results. Longer-term investors willing to wait for Amgen's drug pipeline to mature may be getting their chance to own a proven Ferrari at Ford prices. |
The Motley Fool
January 25, 2008
Brian Lawler |
Amgen: Punched Out or Still Fighting? Amgen manages to pull off a 3.5% increase in revenue for 2007, even with sales of its anemia franchise drugs Aranesp and Epogen down a combined 17% year over year in the fourth quarter. |
The Motley Fool
December 26, 2006
Brian Lawler |
2006 in Review: Amgen For investors in shares of Amgen, it hasn't been a good year. The stock has been down more than 7% year to date. Despite this fact, Amgen has had successes on all fronts this year. |
The Motley Fool
July 30, 2007
Brian Lawler |
Amgen Adjusting Amgen's second quarter reflects the pain it's feeling with its top drugs. Investors, take note. |
The Motley Fool
March 15, 2007
Brian Lawler |
Amgen vs. Intel: Amgen In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Why Amgen deserves to win this match-up. |
The Motley Fool
October 29, 2007
Brian Lawler |
Amgen Revisited Third-quarter financials fail to impress, but there was good news, too from the biotech leader. |
The Motley Fool
July 21, 2006
Brian Lawler |
Amgen's Little Helpers Sluggish earnings are offset by promising drugs in the pipeline. The bottom line with Amgen is that it is one of the best-run biotechs, period. Investors, take note. |
The Motley Fool
January 26, 2010
Brian Orelli |
Timing Is Everything for Amgen Amgen is counting on osteoporosis drug Prolia for a successful 2010. |
The Motley Fool
March 19, 2008
Brian Lawler |
Roche to Amgen: We Surrender Roche gives in to a judge's recommendation that it pay a higher royalty to Amgen on sales of its anemia drug Mircera. |
The Motley Fool
January 29, 2007
Brian Lawler |
No Amplified Growth for Amgen The drug developer recently released its fourth-quarter financial results. With a $71 share price and trading at roughly a forward multiple of 16 times earnings, the stock is not particularly cheap. |
The Motley Fool
May 27, 2009
Brian Orelli |
A Partnership of the Heart Amgen, the large biotech company, exercises its right to license Cytokinetic's cardiac contractility program, including heart failure drug CK-1827452. |
The Motley Fool
December 10, 2007
Brian Lawler |
Amgen Under Review The FDA plans another debate about an Amgen top drug. |
The Motley Fool
October 19, 2010
Brian Orelli |
When the Status Quo Is a Big Win The lack of an FDA rejection will do just fine. Amgen and Johnson & Johnson seemed to get through the FDA advisory panel process without much problem yesterday. |
The Motley Fool
January 27, 2009
Brian Orelli |
Amgen's Anemic Again 2009 won't be stellar, but the future looks better. |
The Motley Fool
October 3, 2008
Brian Orelli |
Amgen Draws Blood in Anemia-Drug War The pharmaceutical fights off rival Roche. |
The Motley Fool
February 23, 2005
Brian Gorman |
Amgen Gets Disciplined Direct-to-consumer advertising may be a non-starter for Amgen and other biotech companies. |
The Motley Fool
December 16, 2003
Rick Aristotle Munarriz |
Amgen's Cannibalistic Ways Amgen's prospects look good, and it is planning a large share buyback. |
The Motley Fool
August 21, 2007
Brian Orelli |
Pushing Pills Spending on drug lobbying increases. What do companies have to show for it? The key for investors is to find drug companies that are spending their money wisely. |
The Motley Fool
January 7, 2010
Brian Orelli |
Warning: Potential Anemic Growth Ahead Anemia-drug makers get more scrutiny from the FDA. |
The Motley Fool
October 21, 2004
W.D. Crotty |
One Value-Priced Biotech Giant Amgen is a growing cash machine selling at the market's multiple to earnings. |
The Motley Fool
February 29, 2008
Brian Lawler |
Amgen Playing Hardball There are new developments in the Amgen and Roche patent fight over their anemia drugs. |
The Motley Fool
July 30, 2010
Brian Orelli |
On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually. |
The Motley Fool
February 27, 2008
Brian Orelli |
Everyone's Picking on Anemia Drugs A new study in The Journal of the American Medical Association is adding fuel to the fire about Amgen's and Johnson & Johnson's anemia drugs. Should investors worry? |
The Motley Fool
October 24, 2006
Brian Lawler |
Amgen's Ho-Hum Quarter With all the money flowing into its coffers, the biotech has no excuse not to start paying a dividend. |
The Motley Fool
March 28, 2008
Brian Lawler |
Amgen and Roche Still Duking It Out Amgen threatens to sue Roche for damages. |
The Motley Fool
June 2, 2010
Brian Orelli |
Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market. |
BusinessWeek
March 22, 2004
Arlene Weintraub |
Amgen Opens The Secret Curtain The biotech leader will host analysts and investors to drum up excitement for its pipeline -- and its stock. Will it work? |
The Motley Fool
August 26, 2009
Brian Orelli |
Amgen Falls Back on the Future Instead of the TREAT trial for Aranesp, Amgen's new cherry is Prolia's potential to treat cancer patients, for which Amgen could get marketing approval next year. |
BusinessWeek
May 15, 2006
Arlene Weintraub |
Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors. |
The Motley Fool
October 20, 2005
Brian Gorman |
Amgen's Drive to Diversify The drugmaker pulled in impressive results with its current portfolio, but a drug in late-stage testing could make the company even more attractive to investors. |
The Motley Fool
September 10, 2007
Brian Lawler |
Get a Glimpse of Amgen's Future Investors will want to pay attention to an FDA advisory panel meeting discussing new labeling recommendations for Amgen's anemia medications. The two drugs represented 44% of the pharmaceutical company's second-quarter revenue. |
The Motley Fool
March 23, 2004
David Nierengarten |
Genentech's Star Power How much higher can Genentech go? |
The Motley Fool
July 28, 2009
Brian Orelli |
Amgen Secures Its Future Earnings and a marketing partnership -- oh my. |
The Motley Fool
September 28, 2006
Brian Lawler |
Amgen Secures Its Future FDA approval for the company's colorectal cancer drug is good news for its future prospects. Investors, take note. |
The Motley Fool
November 11, 2010
Brian Orelli |
Moderate Results, Moderate Rally for Dendreon Sometimes good enough really is good enough. |
The Motley Fool
November 9, 2006
Karl Thiel |
The Best Blue Chip for 2007: Amgen Once a small biotech struggling to make its way in the world, Amgen has grown up. Investors, take note. |
Chemistry World
October 28, 2014
Phillip Broadwith |
Amgen stacks up additional job cuts US biotech heavyweight Amgen is to cut an extra 600 -- 1100 jobs by the end of 2015, on top of the 2900 the company earmarked for the chop in August. |
BusinessWeek
January 14, 2010
Rob Waters |
Amgen: Strengthening Bones, Weakening Cancer? Regulators may soon approve an Amgen drug, denosumab, for osteoporosis, but the payoff could be in oncology. |
The Motley Fool
November 19, 2010
Brian Orelli |
One Drug, Two Names, Two Wildly Different Prospects Amgen double speaks for increased sales. |
